Kyverna appoints Naji Gehchan as Chief Medical and Development Officer; grants 425,000 option shares

Kyverna Therapeutics, Inc.

Naji Gehchan, MD/MBA, joins as Chief Medical and Development Officer; led clinical development at Eli Lilly including imlunestrant.
Inducement grant of options for 425,000 shares under 2024 Inducement Equity Plan; exercise price at Jan 22 closing price.
Options vest over 4 years (25% at 1-year anniversary, remainder monthly thereafter) contingent on continued service.
Dominic Borie, former President of R&D, transitions to Strategic Advisor to the CEO and Board.
Gehchan brings 20+ years experience in immunology and late-stage development for Kyverna's KYV-101 CAR-T program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.